• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

    1/18/22 8:22:46 AM ET
    $RCOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCOR alert in real time by email
    SC 13G/A 1 CHAQ_RCOR_13GA_20220118.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G/A

    (Rule 13d-102)

    Amendment No. 1

     

    Under the Securities Exchange Act of 1934

     

    Renovacor fka Chardan Healthcare Acquisition 2 Corp.

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    75989E106

    (CUSIP Number)

     

    September 02, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    Rule 13d-1(b)¨
    Rule 13d-1(c)x
    Rule 13d-1(d)¨

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

    (Page 1 of 12 Pages)

     

     
     

     

    CUSIP No.  75989E106 Schedule 13G/A Page 2 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    THE K2 Principal Fund, L.P.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ontario, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%

    12

    TYPE OF REPORTING PERSON

    PN

     

      

     
     
    CUSIP No.  75989E106 Schedule 13G/A Page 3 of 12 Pages

      

    1

    NAME OF REPORTING PERSONS

     

    K2 Genpar 2017 Inc.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ontario, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

        

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%

    12

    TYPE OF REPORTING PERSON

    CO

     

     
     
    CUSIP No.  75989E106 Schedule 13G/A Page 4 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    SHAWN KIMEL INVESTMENTS, INC.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    ONTARIO, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

        

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%

    12

    TYPE OF REPORTING PERSON

    CO

     

     
     
    CUSIP No.  75989E106 Schedule 13G/A Page 5 of 12 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    ONTARIO, CANADA

    NUMBER OF SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

       -0-

    6

    SHARED VOTING POWER

        

    7

    SOLE DISPOSITIVE POWER

       -0-

    8

    SHARED DISPOSITIVE POWER

        

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%

    12

    TYPE OF REPORTING PERSON

    CO

      

     
     
    CUSIP No.  75989E106 Schedule 13G/A Page 6 of 12 Pages

      

    Item 1(a).Name of Issuer:

     

    The name of the issuer is Renovacor fka. Chardan Healthcare Acquisition 2 Corp

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    The Company's principal executive offices are located at P.O. BOX 8142, GREENWICH, CT, 06836

     

    Item 2(a).Name of Person Filing:

     

    The persons filing this statement are Shawn Kimel Investments, Inc., an Ontario corporation (“SKI“), The K2 Principal Fund, L.P., an Ontario limited partnership (the “Fund“), K2 Genpar 2017 Inc., an Ontario corporation and the General Partner to the Fund (“Genpar 2017“), and K2 & Associates Investment Management Inc., an Ontario corporation (“K2 & Associates“). Together SKI, the Fund, Genpar2017, and K2 & Associates are the “Reporting Persons“).

     

    Mr. Gosselin is Vice president of SKI, Secretary of Genpar 2017, and President of K2 & Associates. K2 & Associates is a direct 66.5% owned subsidiary of SKI, and is the investment manager of the Fund

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is 2 Bloor St West, Suite 801, Toronto, Ontario, M4W 3E2

     

    Item 2(c).Citizenship:

     

    Mr. Gosselin is a citizen of Canada.

     

    The Fund is an Ontario limited partnership.

     

    Each of SKI and GenPar 2017 Inc and K2 & Associates is an Ontario corporation.

     

    Item 2(d).Title of Class of Securities:

     

    Common Shares

     

    Item 2(e).CUSIP Number:

     

    75989E106

     

     
    CUSIP No.  75989E106 Schedule 13G/A Page 7 of 12 Pages

      

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨   Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨   Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e)¨   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨     An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)¨    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

    (j)¨    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:________________.

     

     
     
    CUSIP No.  75989E106 Schedule 13G/A Page 8 of 12 Pages

      

    Item 4. Ownership:

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The K2 Principal Fund, L.P.

     

    (a) Amount beneficially owned:
    (b) Percent of class: 0.00%
    (c) Number of shares as to which the person has:

      (i)   Sole power to vote or direct the vote: 0
      (ii)   Shared power to vote or direct the vote:
      (iii)   Sole power to dispose or direct the disposition of: 0
      (iv)   Shared power to dispose or direct the disposition of:

     

    K2 Genpar 2017 Inc.

     

    (a) Amount beneficially owned:
    (b) Percent of class: 0.00%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote:
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of:

     

    SHAWN KIMEL INVESTMENTS, INC.

     

    (a) Amount beneficially owned:
    (b) Percent of class: 0.00%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote:
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of:

     

     

     
    CUSIP No.  75989E106 Schedule 13G/A Page 9 of 12 Pages

      

    K2 & Associates Investment Management Inc..

     

    (a) Amount beneficially owned:
    (b) Percent of class: 0.00%
    (c) Number of shares as to which the person has:

      (i) Sole power to vote or direct the vote: 0
      (ii) Shared power to vote or direct the vote:
      (iii) Sole power to dispose or direct the disposition of: 0
      (iv) Shared power to dispose or direct the disposition of:

     

    Common Shares held of record (and may be deemed to be beneficially owned) by The K2 Principal Fund, L.P. See Item 2(a) above for a description of the corporate structure of the Reporting Persons. Each of the Reporting Persons may be deemed to be beneficial owners of the shares of the Issuer's Common Shares that are held by The K2 Principal Fund, L.P. Mr. Daniel Gosselin is vice president of SKI, Secretray of GenPar 2017 and President of K2 & ASSOCIATES, and exercises ultimate voting and investment powers over the shares of the Issuer's Units that are held of record by The K2 Principal Fund, L.P

     

     

    Item 5.         Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]

     

    Item 6.         Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.         Identification and Classification of Members of the Group.

     

    Not applicable.

     

     
     

     

    CUSIP No.  75989E106 Schedule 13G/A Page 10 of 12 Pages

     

    Item 9.         Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.        Certification.

     

    Each of the Reporting Persons hereby makes the following certification:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No.  75989E106 Schedule 13G/A Page 11 of 12 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 18, 2022

      THE K2 PRINCIPAL FUND, L.P.
         
      By: K2 Genpar 2017 Inc., its General Partner
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        Secretary
         
         
      K2 Genpar 2017 Inc.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        Secretary
         
      SHAWN KIMEL INVESTMENTS, INC.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        President
         
         
      /s/ Daniel Gosselin
      K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        President
         

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    CUSIP No.  75989E106 Schedule 13G/A Page 12 of 12 Pages

     

    Exhibit 1

     

    JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: January 18, 2022

      THE K2 PRINCIPAL FUND, L.P.
         
      By: K2 Genpar 2017 Inc., its General Partner
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        Secretary
         
         
      K2 Genpar 2017 Inc.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        Secretary
         
      SHAWN KIMEL INVESTMENTS, INC.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        Vice President
         
         
      K2 & ASSOCIATES INVESTMENT MANAGEMENT INC.
         
      By: /s/ Daniel Gosselin
        Daniel Gosselin
        President
         
         
    Get the next $RCOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCOR

    DatePrice TargetRatingAnalyst
    9/13/2022$9.00Outperform
    Robert W. Baird
    10/14/2021$22.00Buy
    Ladenburg Thalmann
    10/1/2021$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $RCOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Completes Acquisition of Renovacor

      Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

      12/1/22 4:01:00 PM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

      Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

      9/20/22 6:00:00 AM ET
      $RCKT
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

      Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

      10/4/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

      Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

      9/22/21 4:05:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Renovacor Inc. (Amendment)

      SC 13D/A - Renovacor, Inc. (0001799850) (Subject)

      4/5/23 4:31:54 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Renovacor Inc. (Amendment)

      SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

      2/14/23 7:41:31 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Renovacor Inc.

      SC 13D - Renovacor, Inc. (0001799850) (Subject)

      9/21/22 9:00:09 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Renovacor with a new price target

      Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

      9/13/22 7:37:19 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Renovacor with a new price target

      Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

      10/14/21 7:14:33 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Renovacor with a new price target

      Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

      10/1/21 7:39:25 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Renovacor Inc.

      15-12G - Renovacor, Inc. (0001799850) (Filer)

      12/12/22 4:35:37 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:05 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Renovacor Inc.

      EFFECT - Renovacor, Inc. (0001799850) (Filer)

      12/6/22 12:15:13 AM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rtw Investments, Lp

      4 - Renovacor, Inc. (0001799850) (Issuer)

      4/5/23 4:30:43 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Needham Thomas E. Jr.

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:24:00 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lau Joan

      4 - Renovacor, Inc. (0001799850) (Issuer)

      12/5/22 9:23:45 PM ET
      $RCOR
      Biotechnology: Pharmaceutical Preparations
      Health Care